ENHANCING PHYSICAL and COGNITIVE EFFICIENCY in INDIVIDUALS AT RISK of DEMENTIA USING WHOLE-BODY ELECTROMYOSTIMULATION

October 30, 2024 updated by: Giuseppe Calcagno, University of Molise

ENHANCING PHYSICAL and COGNITIVE EFFICIENCY in ELDERLY INDIVIDUALS AT RISK of DEMENTIA USING WHOLE-BODY ELECTROMYOSTIMULATION

This study aimed to evaluate the effectiveness of twelve weeks whole-body electrical muscle stimulation combined with aerobic exercises.

Study Overview

Detailed Description

This study aimed to evaluate the effectiveness of twelve weeks of WB-EMS (whole-body electrical muscle stimulation at 35Hz and 350 μs) combined with aerobic exercises on a treadmill and rowing machine, in improving physical and cognitive performance in older adults, both healthy and at risk of dementia. The results were compared with those obtained from the same training without WB-EMS.

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • CB
      • Campobasso, CB, Italy, 86100
        • Università degli studi del molise

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • age from 55 to 85 years;
  • no simultaneous participation in any type of supervised physical activity;
  • Sedentary lifestyle

Exclusion Criteria:

  • mini-mental state examination (MMSE) score of less than 24;
  • inability to walk for 6 min without assistance;
  • the presence of a medical condition influencing the cognitive and/or motor functions;
  • the presence of any counter indication for the utilisation of EMS, such as cardiovascular diseases, stents, cardiac pacemakers, and diabetes mellitus, verified by medical certification.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental Training Group
The ETG group underwent in two 20-minute training sessions per week, with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimulation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse duration. The intensity of this training modality was set based on heart rate reserve (HRR), starting at 60% HRR in the first week and increasing by 5% every 3 weeks, reaching 80% HRR by the twelfth week.
The ETG group underwent in two 20-minute training sessions per week (12 weeks), with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimu-lation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse dura-tion
Active Comparator: Control group
The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
30-second arm curl test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
30-second sit-to-stand test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
hand grip strength test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
6-minute walking test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
8-foot up and go test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Chair Sit and Reach Test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Soda Pop Test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Tinetti Balance and Gait Test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Mini-Mental State Examination (MMSE)
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Rey's Auditory Verbal Learning Test (RAVLT)
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Stroop Colour and Word Interference Test (SCWT)
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Trail Making Test (TMT)
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Attentional Matrices Test
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Prose recall test ( babcock)
Time Frame: At the end of 12 weeks
At the end of 12 weeks
Frontal Assessment battery (FAB)
Time Frame: At the end of 12 weeks
At the end of 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 7, 2024

Primary Completion (Actual)

May 15, 2024

Study Completion (Actual)

June 30, 2024

Study Registration Dates

First Submitted

October 29, 2024

First Submitted That Met QC Criteria

October 30, 2024

First Posted (Estimated)

November 1, 2024

Study Record Updates

Last Update Posted (Estimated)

November 1, 2024

Last Update Submitted That Met QC Criteria

October 30, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Cognitive Impairment

Clinical Trials on Whole Body Electromyostimulation

Subscribe